Christine M Posavad

Summary

Publications

  1. pmc Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2
    Christine M Posavad
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Vaccine 29:7058-66. 2011
  2. pmc Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons
    Christine M Posavad
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    J Immunol 184:3250-9. 2010
  3. pmc Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system
    Ashok Cattamanchi
    Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Clin Vaccine Immunol 15:1638-43. 2008
  4. ncbi request reprint CTL are inactivated by herpes simplex virus-infected cells expressing a viral protein kinase
    Derek D Sloan
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA
    J Immunol 171:6733-41. 2003
  5. ncbi request reprint Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy
    Christine M Posavad
    Department of Laboratory Medicine, University of Washington, and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Infect Dis 190:693-6. 2004
  6. ncbi request reprint T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?
    Christine M Posavad
    Department of Laboratory Medicine, University of Washington, Seattle, Washington 98104, USA
    J Immunol 170:4380-8. 2003

Collaborators

Detail Information

Publications6

  1. pmc Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2
    Christine M Posavad
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Vaccine 29:7058-66. 2011
    ..A sensitive and specific assay to measure HSV-specific T cell responses is a necessary part of vaccine development and thus we undertook the development of an interferon-γ (IFN-γ) ELISPOT assay to measure T cell responses to HSV-2...
  2. pmc Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons
    Christine M Posavad
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    J Immunol 184:3250-9. 2010
    ..Understanding the mechanism(s) by which such responses are elicited may provide important insights in developing novel strategies for preventing acquisition of sexually acquired HSV-2...
  3. pmc Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system
    Ashok Cattamanchi
    Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Clin Vaccine Immunol 15:1638-43. 2008
    ..A DNA-based vaccination strategy against HSV-2 appears to be safe and may generate a vaccine-specific cellular immune response, but high vaccine doses are likely needed to elicit an immune response in most vaccinees...
  4. ncbi request reprint CTL are inactivated by herpes simplex virus-infected cells expressing a viral protein kinase
    Derek D Sloan
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA
    J Immunol 171:6733-41. 2003
    ..HSV-infected cells require the expression of U(S)3, a viral protein kinase, to transmit the inactivating signal. Elucidation of the molecular nature of this signaling pathway may allow targeted manipulation of CTL function...
  5. ncbi request reprint Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy
    Christine M Posavad
    Department of Laboratory Medicine, University of Washington, and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Infect Dis 190:693-6. 2004
    ..8% vs. 11.3% of days, respectively; P=.001). Thus, mucosal HSV shedding and HSV-2 reactivation were still frequent among treated subjects, even though HAART was associated with fewer days with HSV lesions...
  6. ncbi request reprint T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?
    Christine M Posavad
    Department of Laboratory Medicine, University of Washington, Seattle, Washington 98104, USA
    J Immunol 170:4380-8. 2003
    ..Understanding the basis of these acquired immune responses may be critical in developing effective vaccines for genital herpes...